PIK3CA Mutation Status and Aspirin-Related Increases in Colorectal Cancer Survival
Use of aspirin in colorectal cancer has previously been associated with favorable outcome. In a recent study in the New England Journal of Medicine, Liao et al. report that 5-year cancer-related mortality was reduced by about 80% with regular use of aspirin when patients’ tumors had mutations in the PIK3CA gene. Overall survival was also significantly improved in the mutation-positive group that used aspirin. Aspirin did not have a protective effect against unmutated tumors. Mutations in PIK3CA are detected in the tumors of approximately 20% of patients with colon cancer.
Although further confirmation is needed, the current findings suggest that PIK3CA mutation analysis is an appropriate companion test and predictive biomarker for adjuvant aspirin treatment in colorectal cancer.
PIK3CA Mutation Analysis is available from NeoGenomics. Our test is comprehensive and based on the gold standard bi-directional sequencing of PIK3CA exons 1, 9, and 20, which represent the critical domain of the gene. The test covers both exons analyzed in the NEJM article by Liao et al. (exons 9 and 20).
PIK3CA testing can be ordered individually or as part of the NeoTYPE™ Colorectal Cancer Profile which also includes MSI, BRAF, KRAS, five to eleven other genes significant in solid tumors.
Specimen Requirements for PIK3CA Mutation Analysis:
Turnaround Time: 7 days
Reference: Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596-1606.